공시 • Dec 06
Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million. Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million on December 5, 2022. Decubal, Lactocare, Apobase, Flux, Dailycare and Fludent, which are primarily sold in the Nordics. The acquisition is expected to be final on 1 April, 2023. The annual turnover for the acquired brands is DKK 330 million. 공시 • Aug 17
Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion. Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion on August 16, 2022. Karo Intressenter offered SEK 60 cash per share to acquire 37,231,505 remaining shares of Karo Pharma. As of date of this offer, Karo Intressenter holds 236,023,099 shares in Karo Pharma, corresponding to 86.4%. The consideration payable in respect of the offer is financed in full by funds available to Karo Intressenter by way of an equity commitment letter issued by EQT VIII. Karo Intressenter does not intend to implement any material changes that may impact Karo Pharma’s employees and management, nor to its existing organization and operations, including the terms of employment and the locations where Karo Pharma conducts its business.
Completion of the offer is conditional upon the offer being accepted to such extent that Karo Intressenter becomes the owner of shares representing more than 90% of the total number of outstanding shares in Karo Pharma. In the event that Karo Intressenter obtains more than 90% of the outstanding shares in Karo Pharma, it intends to initiate compulsory redemption proceedings under the Swedish Companies Act to acquire all remaining shares in Karo Pharma.
The acceptance period for the offer is expected to commence on August 18, 2022 and expire on September 15, 2022. SEB Corporate Finance, Skandinaviska Enskilda Banken AB is financial advisor and White & Case is legal advisor to Karo Intressenter in connection with the offer. Roschier Advokatbyrå AB has been appointed as legal advisor of Karo Pharma. 공시 • Apr 03
Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT). Karo Pharma AB (publ) (OM:KARO) entered into an agreement to acquire E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) for an implied enterprise value of £200 million on December 24, 2021. The Proposed Sale, if completed, would be another step forward in Reckitt’s plan to actively manage its portfolio for higher growth, following the recent divestments of its IFCN business in China and its Scholl brand, as well as the acquisition of Biofreeze. The transaction is expected to close in the second quarter of 2022. As of April 1, 2022. All conditions to the completion of the transaction have been satisfied. Matthew Appleton, Gareth Irving, Lydia Challen and Alasdair Balfour of Allen & Overy LLP acted as legal advisor to Reckitt Benckiser Group plc. Centerview Partners UK LLP acted as financial advisor to Reckitt Benckiser Group plc .
Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) on April 1, 2022. 공시 • Mar 28
Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022 Karo Pharma AB (publ) announced that they will report fiscal year 2021 final results on Apr 12, 2022 Reported Earnings • Feb 26
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr0.08 loss per share (down from kr0.37 profit in FY 2020). Revenue: kr2.96b (up 2.7% from FY 2020). Net loss: kr17.5m (down 121% from profit in FY 2020). Revenue missed analyst estimates by 2.3%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance. 공시 • Jan 14
Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others. Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million on November 22, 2021. Under the terms, €290 million will be paid on a cash and debt free basis and a minor additional payment amounting to €10 million may be paid if certain conditions are met in relation to future growth targets for the Sylphar Group. Acquisition also includes the direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (Pro Teeth Whitening), Nutravita Limited (Nutravita) and Alpha Foods BV (Alpha Food), together the Sylphar Group. As part of the transaction, Robin List and its management team as well as the former shareholders of Nutravita and Alpha Foods will reinvest in Karo Pharma. The acquisition will be financed by way of additional credit facilities, including an equity bridge loan facility with a tenor of twelve (12) months, which will be provided by certain of the Karo's existing bank lenders. Robin List, Chief Executive Officer of Sylphar, shall join the Karo Corporate Management Team, reporting to Christoffer Lorenzen, Chief Executive Officer. Robin shall continue to manage the Sylphar businesses and will be instrumental in the integration and forward operations of the combined companies.
For the year ended September 2021, Sylphar International generated sales of approximately €64 million. The transaction is subject to customary competition authority approvals being received. The transaction is expected to be completed during January 2022. Transaction is expected to contribute positively to Karo's market position and further enhance Karo's strong platform for continued growth, particularly in the digital marketplace. Jan Jensen, Patrik Erblad, Tilman Kuhn, Johan Thiman and Oscar Liljeson, Thomas Glauden, Peter Svanqvis of White & Case Advokat AB acted as legal advisor to Karo Pharma AB. Rothschild & Co SCA acted as financial advisor and Argo - BE acted as legal advisor to Vendis Capital, Robin List and the shareholders of Nutravita and Alpha Foods. Ola Sandersson and Malin Leffler of Roschier acted as legal advisors for Vendis Capital and Robin List.
Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others on January 13, 2021. 공시 • Nov 24
Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million. Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million on November 22, 2021. Under the terms, €290 million will be paid on a cash and debt free basis and a minor additional payment amounting to €10 million may be paid if certain conditions are met in relation to future growth targets for the Sylphar Group. Acquisition also includes the direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (Pro Teeth Whitening), Nutravita Limited (Nutravita) and Alpha Foods BV (Alpha Food), together the Sylphar Group. As part of the transaction, Robin List and its management team as well as the former shareholders of Nutravita and Alpha Foods will reinvest in Karo Pharma. The acquisition will be financed by way of additional credit facilities, including an equity bridge loan facility with a tenor of twelve (12) months, which will be provided by certain of the Karo's existing bank lenders.
For the year ended September 2021, Sylphar International generated sales of approximately €64 million. The transaction is subject to customary competition authority approvals being received. The transaction is expected to be completed during January 2022. Transaction is expected to contribute positively to Karo's market position and further enhance Karo's strong platform for continued growth, particularly in the digital marketplace. Jan Jensen, Patrik Erblad, Tilman Kuhn, Johan Thiman and Oscar Liljeson, Thomas Glauden, Peter Svanqvis of White & Case Advokat AB acted as legal advisor to Karo Pharma AB. Rothschild & Co SCA acted as financial advisor and Argo - BE acted as legal advisor to Vendis Capital, Robin List and the shareholders of Nutravita and Alpha Foods. Reported Earnings • Oct 30
Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr738.5m (up 8.7% from 3Q 2020). Net income: kr59.0m (up kr61.8m from 3Q 2020). Profit margin: 8.0% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 129 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 23
Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020) The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: kr747.9m (up 8.6% from 2Q 2020). Net loss: kr21.4m (down 184% from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance. 공시 • Jul 03
Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO). Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO) on July 1, 2021. The portfolio had a turnover of SEK 62 million in 2020.
Evolan Pharma AB completed the acquisition of Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO) on July 1, 2021. Executive Departure • Apr 27
Independent Chairman of the Board Bo Hansen has left the company On the 21st of April, Bo Hansen's tenure as Independent Chairman of the Board ended after 2.2 years in the role. We don't have any record of a personal shareholding under Bo's name. A total of 2 executives have left over the last 12 months. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr713.0m (down 10% from 1Q 2020). Net income: kr53.3m (down 39% from 1Q 2020). Profit margin: 7.5% (down from 11% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 02
Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Reported Earnings • Feb 20
Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. 공시 • Feb 17
Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021 Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021, at 15:00 Central European Standard Time. Location: Näringslivets Hus Stockholm Sweden 공시 • Feb 04
Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million. Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million on February 3, 2021. European OTC brand portfolio comprises of Flux, Decubal, Lactocare, Apobase, Dailycare and Fludent. For the year ended 2020, European OTC brand portfolio reported a revenue of €35 million. The transaction is financed with existing cash and is expected to close on April 1, 2021. Is New 90 Day High Low • Jan 27
New 90-day low: €4.81 The company is down 24% from its price of €6.32 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period. Is New 90 Day High Low • Jan 08
New 90-day low: €5.08 The company is down 25% from its price of €6.80 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: €5.38 The company is down 20% from its price of €6.74 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 05
New 90-day low: €5.87 The company is down 7.0% from its price of €6.28 on 04 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. 공시 • Nov 18
J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million. J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million on November 16, 2020. Swereco AB reported revenues of SEK 118 million on December 31, 2019. The transaction is expected to close in December 1, 2020. Reported Earnings • Nov 05
Third quarter 2020 earnings released: kr0.013 loss per share The company reported a mediocre third quarter result with increased losses, although revenues were improved. Third quarter 2020 results: Revenue: kr679.1m (up 53% from 3Q 2019). Net loss: kr2.76m (loss widened 53% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of kr86.1m, up 46% from the prior year. Total revenue was kr2.81b over the last 12 months, up 64% from the prior year. 공시 • Jul 21
Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021 Karo Pharma AB (publ) announced that they will report fiscal year 2020 results on Feb 18, 2021 